ArticleBlood advances2023
Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review.European journal of haematology · 2026Pooled it
- Surgical management of sickle cell retinopathy: a systematic review of clinical outcomes and a single-arm meta-analysis of single-surgery anatomical success.Frontiers in ophthalmology · 2026Pooled it
- EHA Guidelines on the management of children and adults with hemoglobin SC disease.HemaSphere · 2026Article
- Retinal Challenges in Sickle Cell Patients-Present and Future: A Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Circulating angiogenesis-related biomarkers in sickle cell retinopathy and maculopathy.British journal of haematology · 2026Article
- Loss to Follow-Up Rates Among Pediatric Sickle Cell Disease Patients in an Ophthalmology Clinic.Journal of vitreoretinal diseases · 2026Article
- The role of hemoglobin F in sickle cell disease complications: a descriptive secondary analysis.Blood vessels, thrombosis & hemostasis · 2026Article
- Ultra-Widefield Retinal Imaging versus Dilated Fundus Examination for the Detection of Sickle Cell Retinopathy: A Systematic Review of Diagnostic Test Accuracy Studies.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Prevalence of ocular complications of sickle cell disease in children seen at a tertiary health facility in Southern Ghana.Journal of sickle cell disease · 2026Article
- Article
- The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy.British journal of haematology · 2025Article
- Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.Haematologica · 2025Article
- Cerebral hemodynamics and oxygen metabolism in patients with milder and severe forms of sickle cell disease and thalassemia.HemaSphere · 2024Article
- Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis.Haematologica · 2024Article
- Sickle Cell Disease Related Vasculopathies and Early Evaluation in a Pediatric Population.In vivo (Athens, Greece)Article
- Automated Quantitative Assessment of Retinal Vascular Tortuosity in Patients with Sickle Cell Disease.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD). Proliferative SCR (PSCR) can lead to severe visual impairment due to vitreous hemorrhage or retinal detachment. Knowledge of risk factors for progression and complications of SCR is limited. The aim of this study is to describe the natural history of SCR and to identify risk factors for progressive SCR and development of PSCR. We retrospectively analyzed disease progression in 129 patients with SCD with a median follow-up period of 11 years (interquartile range, 8.5-12). Patients were divided in 2 groups. The genotypes hemoglobin SS (HbSS), HbSβ0-thalassemia, and HbSβ+-thalassemia were grouped together (n = 83; 64.3%), whereas patients with HbSC (n = 46; 35.7%) were grouped separately. Progression of SCR was observed in 28.7% (37 of 129) of patients. Older age (adjusted odds ratio [aOR], 1.073; 95% confidence interval [CI], 1.024-1.125; P = .003), HbSC genotype (aOR, 25.472; 95% CI, 3.788-171.285; P ≤ 0.001), and lower HbF (aOR, 0.786; 95% CI, 0.623-0.993; P = .043) were associated with PSCR at end of follow-up. Lack of any SCR at end of follow-up was associated with female sex (aOR, 2.555; 95% CI, 1.101-5.931; P = .029), HbSS/HbSβ0/HbSβ+ genotype (aOR, 3.733; 95% CI, 1.131-12.321; P = .031), and higher HbF levels (aOR, 1.119; 95% CI, 1.007-1.243; P = .037). Differentiated strategies for screening and follow-up of SCR could be considered for patients at low or high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.